Ke. Andersson et al., The effect of sildenafil on apomorphine-evoked increases in intracavernouspressure in the awake rat, J UROL, 161(5), 1999, pp. 1707-1712
Purpose: The aim of this study was to develop a quantitative, awake animal
model to investigate the effect of sildenafil on centrally-evoked erectile
activity.
Methods: Intracavernous pressures were recorded in awake, male Sprague Dawl
ey rats after administration of apomorphine (100 or 250 mu g./kg. subcutane
ously). Sildenafil (100 mu g./kg. intravenously) was then given 10 min. aft
er a second dose of apomorphine. The time to first response, duration of re
sponse, and peak intracavernous pressure and area under the response, were
measured before and after sildenafil.
Results: Apomorphine produced rhythmic increases in intracavernous pressure
. The pressure increase consisted of two components. The amplitude of the f
irst, tonic response was 58 +/- 3 mm. Hg, and a superimposed, burst like in
crease in pressure elevated this further to 81 +/- 6 mm. Hg. Bilateral tran
section of the pudendal nerves abolished the burstlike pressure changes; bi
lateral transection of the cavernous nerves prevented both responses. The d
uration of the apomorphine-induced increase in intracavernous pressure was
significantly(p = 0.003) prolonged by sildenafil (100 mu g./kg.) from 37 +/
- 4 to 62 +/- 11 s (n = 6). The overall intracavernous pressure response to
apomorphine (100 mu g./kg.), measured as the area under the curve, was sig
nificantly (p = 0.003) increased by sildenafil (100 mu g./kg.) from 67 +/-
8 to 142 +/- 31 units (n = 6). N-nitro-L-arginine methyl ester (40 mg./kg.
intravenously) prevented the apomorphine-induced responses.
Conclusions: Monitoring intracavernous pressures in the awake rat represent
s a simple model to evaluate the effect of drugs on erectile function. Usin
g this model we have shown that apomorphine elicits a rise in intracavernou
s pressure that can be prolonged by sildenafil. These results suggest that
there may be a role for the combination of apomorphine and sildenafil in th
e management of erectile dysfunction.